WallStSmart

Eli Lilly and Company (LLY)vsQT Imaging Holdings, Inc. Common Stock (QTI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 318782% more annual revenue ($72.25B vs $22.66M). LLY leads profitability with a 35.0% profit margin vs -58.9%. LLY earns a higher WallStSmart Score of 78/100 (B+).

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.06

QTI

Avoid

27

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -2.06

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$948.95B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.9%10/10

Earnings expanding 169.9% YoY

QTI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
133.4%10/10

Revenue surging 133.4% year-over-year

Areas to Watch

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.393/10

Elevated debt levels

Price/BookValuation
32.4x2/10

Trading at 32.4x book value

QTI4 concerns · Avg: 3.5/10
Price/BookValuation
13.4x4/10

Trading at 13.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$50.98M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.533/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bull Case : QTI

The strongest argument for QTI centers on Revenue Growth. Revenue growth of 133.4% demonstrates continued momentum.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.

Bear Case : QTI

The primary concerns for QTI are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 1.53 is elevated, increasing financial risk.

Key Dynamics to Monitor

LLY profiles as a growth stock while QTI is a hypergrowth play — different risk/reward profiles.

LLY carries more volatility with a beta of 0.48 — expect wider price swings.

QTI is growing revenue faster at 133.4% — sustainability is the question.

LLY generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (78/100 vs 27/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

QT Imaging Holdings, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

QT Imaging Holdings, Inc. engages in the manufacturing, research, and development of automated breast imaging system for producing high-resolution transmission ultrasound images. The company is headquartered in Novato, California.

Want to dig deeper into these stocks?